Last 529.50 GBp
Change Today +8.50 / 1.63%
Volume 544.4K
As of 11:35 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

btg plc (BTG) Snapshot

Open
520.00 GBp
Previous Close
521.00 GBp
Day High
532.00 GBp
Day Low
520.00 GBp
52 Week High
01/21/14 - 624.00 GBp
52 Week Low
05/23/13 - 323.10 GBp
Market Cap
1.9B
Average Volume 10 Days
887.4K
EPS TTM
0.06 GBp
Shares Outstanding
361.6M
EX-Date
06/7/00
P/E TM
85.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for BTG PLC (BTG)

Related News

No related news articles were found.

btg plc (BTG) Related Businessweek News

No Related Businessweek News Found

btg plc (BTG) Details

BTG plc, a specialist healthcare company, engages in developing and commercializing products targeting critical care, cancer, and varicose veins. It operates through three segments: Specialty Pharmaceuticals, Interventional Medicine, and Licensing & Biotechnology. The company markets and sells specialty pharmaceuticals, including CroFab, a snake bite antivenom to treat envenomation from North American pit viper snakes; DigiFab, an antidote to treat patients with life-threatening toxicity resulting from treatment with digoxin; and Voraxaze for the treatment of life-threatening toxicity due to renal impairment resulting from treatment with high-dose methotrexate. It also offers a range of interventional oncology products comprising Bead Block, LC Bead, and DC Bead used to treat patients with hypervascularized tumours and arteriovenous malformations; and brachytherapy products, primarily implantable seeds used to deliver low-dose radiation to localized prostate tumours. In addition, the company provides Varisolve, which is in new drug application stage for the treatment of varicose veins. Its products in development stage include PARAGON Bead, a drug-eluting bead that is in Phase II clinical trial to treat metastatic colorectal cancer; PRECISION Bead, a Phase II clinical trial product for the treatment of primary liver cancer; and Alemtuzumab, a Phase III clinical trial product used in the treatment of relapsing multiple sclerosis. The company’s licensing and biotechnology products comprise Zytiga, a Phase II clinical product for the treatment of advanced prostate cancer; and Two-Part Hip Cup, a prosthetic hip joint replacement licensed to hip-replacement technology manufacturers. BTG plc was founded in 1948 and is headquartered in London, the United Kingdom.

570 Employees
Last Reported Date: 06/17/13
Founded in 1948

btg plc (BTG) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 944.0K GBP
Chief Financial Officer, Director and Chairma...
Total Annual Compensation: 700.0K GBP
Compensation as of Fiscal Year 2013.

btg plc (BTG) Key Developments

BTG Mulls Acquisitions

BTG plc (LSE:BTG) intends to make acquisitions. Ots future growth strategy includes expanding uses of existing products, growing overseas sales in the European Union and Asia, and continuing to seek out acquisition opportunities.

BTG plc Provides Revenue Guidance for the Year Ending March 31, 2014

BTG plc provided revenue guidance for the year ending March 31, 2014. The company reiterates its guidance of revenue in the range £275 million to £285 million for the current financial year ending March 31, 2014.

BTG plc Reiterates Revenue Guidance for the Fiscal Year Ending March 31, 2014

BTG plc reported provides trading guidance for the period from October 1, 2013 to January 28, 2014 and for the full year ending March 31, 2014. For the period, the company reported trading overall during the period and in the year to date has been in line with expectations. For the financial year, the company reiterates its guidance of revenue in the range £275 million to £285 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BTG:LN 529.50 GBp +8.50

BTG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Merit Medical Systems Inc $13.05 USD -0.38
Pfizer Ltd/India 1,235 INR +3.95
RPX Corp $16.71 USD +0.31
Skyepharma PLC 223.00 GBp +14.00
Wi-Lan Inc C$3.23 CAD -0.03
View Industry Companies
 

Industry Analysis

BTG

Industry Average

Valuation BTG Industry Range
Price/Earnings 86.8x
Price/Sales 7.9x
Price/Book 3.6x
Price/Cash Flow 57.1x
TEV/Sales 8.2x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BTG PLC, please visit www.btgplc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.